株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

興和 - 製品パイプライン分析

Kowa Company, Ltd. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 214154
出版日 ページ情報 英文 53 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.52円で換算しております。
Back to Top
興和 - 製品パイプライン分析 Kowa Company, Ltd. - Product Pipeline Review - 2016
出版日: 2016年08月17日 ページ情報: 英文 53 Pages
概要

興和 は日本に本社を置く多角経営企業で、繊維、機械、建設資材、薬品、医療機器、省エネ製品などの開発・製造・販売を行っています。

当レポートでは、興和における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

興和 の基本情報

  • 興和 の概要
  • 主要情報
  • 企業情報

興和 :R&Dの概要

  • 主な治療範囲

興和 :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

興和 :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 登録申請前の製品/併用療法モダリティ
    • 第Ⅲ相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第Ⅱ相の製品/併用療法モダリティ
    • 第Ⅰ相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ
  • 開発段階が不明のパイプライン製品
    • 開発段階が不明の製品/併用療法モダリティ

興和 :薬剤プロファイル

  • pitavastatin
  • anagliptin
  • K-103IP
  • K-877
  • peretinoin
  • K-134
  • pitavastatin CR
  • ripasudil
  • epirubicin hydrochloride
  • K-312
  • Small Molecule to Inhibit Acyl-Coenzyme A for Undisclosed Indication
  • Small Molecule for Oncology
  • K-163SZ

興和 :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

興和 :最新のパイプライン情報

興和 :開発休止中のプロジェクト

興和 :企業理念

興和 :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

目次
Product Code: GMDHC08120CDB

Summary:

Global Markets Direct's, 'Kowa Company, Ltd. - Product Pipeline Review - 2016', provides an overview of the Kowa Company, Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kowa Company, Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Kowa Company, Ltd.
  • The report provides overview of Kowa Company, Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Kowa Company, Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Kowa Company, Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Kowa Company, Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kowa Company, Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kowa Company, Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Kowa Company, Ltd. Snapshot
    • Kowa Company, Ltd. Overview
    • Key Information
    • Key Facts
  • Kowa Company, Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Kowa Company, Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Kowa Company, Ltd. - Pipeline Products Glance
    • Kowa Company, Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Kowa Company, Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Kowa Company, Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Kowa Company, Ltd. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Kowa Company, Ltd. - Drug Profiles
    • pemafibrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • anagliptin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • peretinoin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-134
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ripasudil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • epirubicin hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-312
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pitavastatin NP
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Agonize LXRB for Atherosclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Acyl-Coenzyme A for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • K-163SZ
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kowa Company, Ltd. - Pipeline Analysis
    • Kowa Company, Ltd. - Pipeline Products by Target
    • Kowa Company, Ltd. - Pipeline Products by Route of Administration
    • Kowa Company, Ltd. - Pipeline Products by Molecule Type
    • Kowa Company, Ltd. - Pipeline Products by Mechanism of Action
  • Kowa Company, Ltd. - Recent Pipeline Updates
  • Kowa Company, Ltd. - Dormant Projects
  • Kowa Company, Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • pitavastatin CR
  • Kowa Company, Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kowa Company, Ltd., Key Information
  • Kowa Company, Ltd., Key Facts
  • Kowa Company, Ltd. - Pipeline by Indication, 2016
  • Kowa Company, Ltd. - Pipeline by Stage of Development, 2016
  • Kowa Company, Ltd. - Monotherapy Products in Pipeline, 2016
  • Kowa Company, Ltd. - Partnered Products in Pipeline, 2016
  • Kowa Company, Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Kowa Company, Ltd. - Pre-Registration, 2016
  • Kowa Company, Ltd. - Phase III, 2016
  • Kowa Company, Ltd. - Phase II, 2016
  • Kowa Company, Ltd. - Phase I, 2016
  • Kowa Company, Ltd. - Preclinical, 2016
  • Kowa Company, Ltd. - Discovery, 2016
  • Kowa Company, Ltd. - Unknown, 2016
  • Kowa Company, Ltd. - Pipeline by Target, 2016
  • Kowa Company, Ltd. - Pipeline by Route of Administration, 2016
  • Kowa Company, Ltd. - Pipeline by Molecule Type, 2016
  • Kowa Company, Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Kowa Company, Ltd. - Recent Pipeline Updates, 2016
  • Kowa Company, Ltd. - Dormant Developmental Projects,2016
  • Kowa Company, Ltd. - Discontinued Pipeline Products, 2016
  • Kowa Company, Ltd., Other Locations
  • Kowa Company, Ltd., Subsidiaries

List of Figures

  • Kowa Company, Ltd. - Pipeline by Top 10 Indication, 2016
  • Kowa Company, Ltd. - Pipeline by Stage of Development, 2016
  • Kowa Company, Ltd. - Monotherapy Products in Pipeline, 2016
  • Kowa Company, Ltd. - Partnered Products in Pipeline, 2016
  • Kowa Company, Ltd. - Pipeline by Top 10 Target, 2016
  • Kowa Company, Ltd. - Pipeline by Route of Administration, 2016
  • Kowa Company, Ltd. - Pipeline by Molecule Type, 2016
  • Kowa Company, Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top